Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (002399.SZ)
Shenzhen, CN
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. is an international pharmaceutical enterprise specializing in the production and commercialization of medicinal products. Its operations span Hong Kong, the United States, Europe, Mainland China, and numerous other global markets. The company's business activities are structured into four primary segments: Finished Dose Pharmaceutical Products, Active Pharmaceutical Ingredients (API), Contract Development and Manufacturing Organization (CDMO), and an 'Others' category. Within its product portfolio, key offerings include finished dose pharmaceuticals, notably enoxaparin sodium injection. Its API division supplies critical ingredients such as heparin sodium API and enoxaparin sodium API, alongside other compounds like pancreatin API. Beyond core products, Hepalink provides a suite of services encompassing research and development, manufacturing, quality management, and program management. This also extends to the creation and production of recombinant pharmaceutical products, essential non-viral vectors, intermediates for gene therapy, and naturally derived pharmaceutical compounds. The group further diversifies its operations into areas such as property management, investment management and consulting, and equity and venture capital. It also engages in biopharmaceutical technology development and consulting, alongside the research, development, and production of biopharmaceuticals. Additional revenue streams include the production and sale of heparin sodium, various pharmaceutical-related service provisions, and the trading of medical and biopharmaceutical products. Established in 1998, the company is headquartered in Shenzhen, People's Republic of China. It adopted its current name, Shenzhen Hepalink Pharmaceutical Group Co., Ltd., in February 2017, having previously operated as Shenzhen Hepalink Pharmaceutical Co.,Ltd.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +2.16% | -3.21% | -7.71% | -17.30% | -15.83% | -15.69% | -14.38% | -16.40% | -39.65% | -40.87% | -81.84% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 1 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+4.2% Q1'26: -4.5% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%-45.5% Q1'26: +18.2% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+21.5% Q1'26: +26.7% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+8.7% Q1'26: +16.6% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+3.6% Q1'26: +6.9% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%-0.2% ★ Q1'26: +0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×2.49× ★ Q1'26: 3.16× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
2.29B
est: 3.53B (-35.1%)
|
2.26B
est: 4.12B (-45.2%)
|
4.81B
est: 4.81B (+0.1%)
|
4.62B
est: 4.79B (-3.5%)
|
5.33B
est: 5.42B (-1.6%)
|
6.32B
est.
|
6.37B
est: 7.29B (-12.7%)
|
5.43B
est: 5.08B (+6.9%)
|
7.16B
est: 5.08B (+41.0%)
|
5.26B
est: 5.21B (+0.9%)
|
5.48B
est: 5.49B (-0.2%)
|
5.73B
5.73B – 5.73B
+4.4% YoY
|
6.10B
6.10B – 6.10B
+6.4% YoY
|
6.46B
6.46B – 6.46B
+6.0% YoY
|
| EBITDA |
875.86M
est: 570.39M (+53.6%)
|
743.43M
est: 665.65M (+11.7%)
|
1.15B
est: 776.40M (+48.5%)
|
1.85B
est: 773.57M (+139.0%)
|
1.88B
est: 874.81M (+114.4%)
|
1.02B
est.
|
693.81M
est: 1.18B (-41.1%)
|
-366.74M
est: 819.93M (-144.7%)
|
1.36B
est: 819.93M (+66.0%)
|
1.16B
est: 632.52M (+83.5%)
|
846.59M
est: 666.33M (+27.1%)
|
695.63M
695.63M – 695.63M
+4.4% YoY
|
740.01M
740.01M – 740.01M
+6.4% YoY
|
784.56M
784.56M – 784.56M
+6.0% YoY
|
| EBIT |
777.96M
est: 397.34M (+95.8%)
|
581.65M
est: 463.70M (+25.4%)
|
929.65M
est: 540.85M (+71.9%)
|
1.59B
est: 538.88M (+195.7%)
|
1.60B
est: 609.40M (+162.8%)
|
711.17M
est.
|
423.89M
est: 820.08M (-48.3%)
|
-689.64M
est: 571.17M (-220.7%)
|
1.09B
est: 571.17M (+90.3%)
|
879.72M
est: 359.81M (+144.5%)
|
473.68M
est: 379.04M (+25.0%)
|
395.71M
395.71M – 395.71M
+4.4% YoY
|
420.95M
420.95M – 420.95M
+6.4% YoY
|
446.30M
446.30M – 446.30M
+6.0% YoY
|
| Net Income |
579.78M
est: 733.65M (-21.0%)
|
396.89M
est: 944.57M (-58.0%)
|
591.46M
est: 733.65M (-19.4%)
|
1.06B
est: 1.27B (-16.8%)
|
1.02B
est: 943.96M (+8.5%)
|
579.58M
est.
|
240.79M
est: 855.92M (-71.9%)
|
-783.26M
est: -212.76M (-268.1%)
|
727.43M
est: -212.76M (+441.9%)
|
646.74M
est: 652.90M (-0.9%)
|
349.49M
est: 352.13M (-0.8%)
|
711.59M
711.59M – 711.59M
+102.1% YoY
|
799.62M
799.62M – 799.62M
+12.4% YoY
|
872.98M
872.98M – 872.98M
+9.2% YoY
|
| SGA |
376.75M
est: 592.81M (-36.4%)
|
431.76M
est: 691.80M (-37.6%)
|
666.78M
est: 806.91M (-17.4%)
|
764.26M
est: 803.96M (-4.9%)
|
821.65M
est: 909.18M (-9.6%)
|
1.06B
est.
|
850.68M
est: 1.22B (-30.5%)
|
1.19B
est: 852.15M (+39.9%)
|
975.69M
est: 852.15M (+14.5%)
|
1.03B
est: 804.85M (+27.7%)
|
478.17M
est: 847.86M (-43.6%)
|
885.14M
885.14M – 885.14M
+4.4% YoY
|
941.61M
941.61M – 941.61M
+6.4% YoY
|
998.30M
998.30M – 998.30M
+6.0% YoY
|
| EPS |
0.46
est: 0.50 (-8.0%)
|
0.32
est: 0.64 (-50.3%)
|
0.47
est: 0.50 (-6.0%)
|
0.85
est: 0.87 (-2.1%)
|
0.76
est: 0.64 (+18.1%)
|
0.40
est.
|
0.16
est: 0.58 (-72.6%)
|
-0.53
est: -0.15 (-265.5%)
|
0.50
est: -0.15 (+444.8%)
|
0.44
est: 0.45 (-1.1%)
|
0.24
est: 0.24 (+0.0%)
|
0.49
0.49 – 0.49
+102.1% YoY
|
0.55
0.55 – 0.55
+12.4% YoY
|
0.60
0.60 – 0.60
+9.2% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-28 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-27 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-26 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-25 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-22 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-21 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-20 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-19 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-18 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-15 | B | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-14 | B | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-13 | B | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-12 | B | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-11 | B | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-08 | B | 3/5 | 3/5 | 2/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-07 | B | 3/5 | 3/5 | 2/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-06 | B | 3/5 | 3/5 | 2/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-30 | B | 3/5 | 4/5 | 2/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-29 | B | 3/5 | 4/5 | 2/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-28 | B | 3/5 | 4/5 | 2/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-27 | B | 3/5 | 4/5 | 2/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-24 | B | 3/5 | 4/5 | 2/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-23 | B | 3/5 | 4/5 | 2/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-22 | B | 3/5 | 4/5 | 2/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-21 | B | 3/5 | 3/5 | 2/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-20 | B | 3/5 | 3/5 | 2/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-17 | B | 3/5 | 3/5 | 2/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-16 | B | 3/5 | 4/5 | 2/5 | 4/5 | 2/5 | 1/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | State Street SPDR S&P China ETF GXC | 0.02% | 82.5K | 0.59% |
| 2 | Xtrackers Emerging Markets Carbon Reduction and Climate Improvers ETF EMCR | 0.00% | 2.5K | 0.15% |
| 3 | State Street SPDR Portfolio Emerging Markets ETF SPEM | 0.00% | 475.5K | 0.07% |
| 4 | Vanguard FTSE Emerging Markets UCITS ETF (USD) Accumulating VFEA.L | 0.00% | 46.5K | 0.17% |
| 5 | Vanguard FTSE Emerging Markets UCITS ETF (USD) Distributing VDEM.L | 0.00% | 46.5K | 0.17% |
| 6 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.00% | 20.1K | 0.26% |
| 7 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.00% | 8.9K | 0.48% |
| 8 | Vanguard FTSE Emerging Markets ETF VWO | 0.00% | 994.4K | 0.06% |
| 9 | Invesco FTSE All-World UCITS ETF FWRA.SW | 0.00% | 22.9K | 0.15% |
| 10 | Invesco FTSE All-World UCITS ETF FTWG.L | 0.00% | 22.9K | 0.15% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Ping Zhang | Executive Director | 5M | male |
| Li Li | Co-Founder, Executive Chairman of the Board & President | 3M | male |
| Yu Shan | Co-Founder, GM, Group Vice President & Executive Director | 3M | male |
| Tan Li | Co-founder, VP, Deputy GM & Executive Director | 2M | female |
| Xi Gao | Senior Vice President of Global Supply Chain | — | male |
| Sze Ting Chan | Joint Company Secretary | — | female |
| Juan Chen | Vice President of Finance, Chief Financial Officer & Financial Controller | — | female |
| Fengqi Qian | Company Secretary | — | male |
| Tao Han | Chief Business Officer | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 002399.SZ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
